Stocks and Finance

Human Genome Sciences

Human Genome Sciences 5/17/2012

06:15 : Human Genome Sciences (HGSI) announces adoption of short-term stockholder - Human Genome Sciences (HGSI) announces adoption of short-term stockholder rights plan, with a term of one year. Also says its board of directors unanimously determines GlaxoSmithKline's (GSK) unsolicited tender offer is inadequate ...
Source : seekingalpha-com

Human Genome Sciences 5/9/2012

10:22 : GlaxoSmithKline Launches Hostile Takeover Bid for Human Genome Sciences - GlaxoSmithKline Plc (NYSE: GSK) will begin a $2.6 billion hostile takeover bid for Human Genome Sciences (NASDAQ: HGSI), the company announced Wednesday.
Source : ibtimes-com
07:45 : DealBook: Glaxo to Make Hostile Bid for Human Genome Sciences - GlaxoSmithKline plans to take its bid for Human Genome Sciences directly to shareholders this week, after being rejected by the biotechnology company last month.
Source : nytimes-com

Human Genome Sciences 4/25/2012

02:42 : Human Genome Sciences (HGSI) said yesterday it's reviewing its strategic ... - Human Genome Sciences (HGSI) said yesterday it's reviewing its strategic options, including a possible sale of the company. Human Genome rejected a $13/share bid from Glaxo last week and is likely hoping for a price in the ...
Source : seekingalpha-com

Human Genome Sciences 4/19/2012

11:21 : Human Genome Sciences rejects takeover bid - Biotech firm Human Genome Sciences announced Thursday that it had rejected a takeover bid from pharmaceutical giant GlaxoSmithKline that valued it at just over 80% of its closing price Wednesday.
Source : cnnmoney-com
10:30 : Not the Human Genome Sciences bid we were waiting for - British pharmaceutical giant GlaxoSmithKline plc has offered to acquire Human Genome Sciences Inc. for $13 per share, valuing the Rockville biotech at about $2.6 billion. "No thanks,” HGS replied. Sure – that’s a big premium ...
Source : bizjournals-com
07:31 : Glaxo Bids for Human Genome Sciences - GlaxoSmithKline launched an unsolicited $2.6 billion offer for longtime research partner Human Genome Sciences, making a bet on the sales prospects of several drugs the companies are developing or marketing together.
Source : wsj-com
05:18 : Human Genome Sciences rebuffs $13-share Glaxo bid - TEL AVIV (MarketWatch) -- Human Genome Sciences Inc., the Rockville, Md., biopharma firm, received and rejected as inadequate a $13-a-share takeover proposal from GlaxoSmithKline PLC, the U.K. health-care major. In a Thursday ...
Source : marketwatch-com
04:51 : Human Genome Sciences (HGSI) turns down an unsolicited offer of $13/share - Human Genome Sciences (HGSI) turns down an unsolicited offer of $13/share from GlaxoSmithKline (GSK) as undervaluing the company. However Human Genome says it's exploring "strategic alternatives," which could include a sale, ...
Source : seekingalpha-com

Human Genome Sciences 3/12/2012

09:38 : Shares of Human Genome Sciences ([[HGSI]] -7.1%) slide lower, extending ... - Shares of Human Genome Sciences (HGSI -7.1%) slide lower, extending a month-long losing streak that has seen HGSI's value diminish by over 20%. The negative sentiment has been driven in part by the fading belief that Glaxo ...
Source : seekingalpha-com

Human Genome Sciences 2/27/2012

20:10 : More on Human Genome Sciences (HGSI): Q4 beats estimates across the board. - More on Human Genome Sciences (HGSI): Q4 beats estimates across the board. Revenue jumped 113% Y/Y on strong sales of Benlysta and lower R&D expenses. Shares +2.7% AH. Post your comment!
Source : seekingalpha-com

Human Genome Sciences 11/2/2011

11:45 : Human Genome Sciences falls on note offering - Rockville-based Human Genome Sciences Inc. stock briefly touched to a two-year low in Wednesday trading after the company said it would sell $400 million in new debt that could be converted to company stock. The company’s ...
Source : bizjournals-com

Human Genome Sciences 10/26/2011

08:31 : Human Genome Sciences (HGSI) is down 13.6% premarket after missing Q3 ... - Human Genome Sciences (HGSI) is down 13.6% premarket after missing Q3 estimates, and guiding for its year-end cash balance to be well below prior forecasts. Piper expects shares to "test recent lows," but nonetheless remains ...
Source : seekingalpha-com

Human Genome Sciences 10/17/2011

18:27 : GlaxoSmithKline (GSK) may bid $25/share for Human Genome Sciences (HGSI), - GlaxoSmithKline (GSK) may bid $25/share for Human Genome Sciences (HGSI), the Daily Mail speculates, citing their partnership in developing the FDA-approved lupus drug Benlysta. With Merck (MRK) and Biogen (BIIB) ...
Source : seekingalpha-com

Human Genome Sciences 9/30/2011

11:15 : Shares of Human Genome Sciences ([[HGSI]] -5.4%) take a hit after reports - Shares of Human Genome Sciences (HGSI -5.4%) take a hit after reports say U.K. regulators are considering not providing coverage for its lupus drug Benlysta. The decision looks controversial after the drug already won U.S. ...
Source : seekingalpha-com

Human Genome Sciences 9/21/2011

11:46 : Human Genome Sciences ([[HGSI]] +12.6%) pops on positive comments from ... - Human Genome Sciences (HGSI +12.6%) pops on positive comments from Piper Jaffray, saying Benlysta sales rose 33% in August. Piper believes the data coincides with the company's claim that physicians are getting more comfortable ...
Source : seekingalpha-com

Human Genome Sciences 8/23/2011

07:04 : Shares of Human Genome Sciences (HGSI) are up 2.6% premarket after Brean ... - Shares of Human Genome Sciences (HGSI) are up 2.6% premarket after Brean Murray initiates its rating on the firm with a Buy and a $22 PT. The stock closed yesterday just a hair above its 52-week low. Post your comment!
Source : seekingalpha-com

Human Genome Sciences 5/27/2011

07:55 : Analyst Research on Gilead Sciences Inc. and Human Genome Sciences Inc. ... - JOHANNESBURG, SOUTH AFRICA--(Marketwire - May 27, 2011) - www.stockcall.com/ offers investors comprehensive research on the Biotechnology industry and has completed analytical research on Gilead Sciences Inc. (NASDAQ: GILD) and ...
Source : marketwire-com
actualidad Human Genome Sciences -


Biotechnology

Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts